| Document |
Document Title |
|
WO/1998/021952A1 |
This invention is concerned with improved processes for reductive alkylation of glycopeptide antibiotics, the improvement residing in employing pyridine-borane as reducing agent.
|
|
WO/1998/022121A1 |
This invention is concerned with improved processes for reductive alkylation of glycopeptide antibiotics. The improvement residing in providing a source of copper which results in the initial production of a copper complex of the glycope...
|
|
WO/1998/016240A1 |
Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or dire...
|
|
WO/1998/016555A1 |
Novel transition metal salts of a polypeptide represented by formula (1), having a high antiviral activity against human immunodeficiency virus (HIV). These compounds stably exhibit an anti-HIV activity higher than the one exhibited by i...
|
|
WO/1998/016198A1 |
The present invention provides glycophospholipid and peptide-phospholipid conjugates comprising a phospholipid moiety and a saccharide or peptide moiety joined by an ether linkage comprising a secondary or tertiary amine. The conjugate s...
|
|
WO/1998/015573A1 |
The invention concerns camptothecin glycoconjugates in which at least one carbohydrate component is suitably linked to camptothecin via an oligopeptide bridge. The invention further concerns processes for preparing the compounds accordin...
|
|
WO/1998/014468A1 |
The invention concerns glycoconjugates of camptothecin derivatives in which at least one carbohydrate component is linked via suitable spacers to the A- or B-ring of a camptothecin derivative. The invention further concerns processes for...
|
|
WO/1998/013378A1 |
T cells mediate specific immune reactions. They recognize (foreign) protein fragments - peptides - that are bound in the peptide binding groove of MHC molecules. These peptide MHC complexes are generated intracellularly and subsquently t...
|
|
WO/1998/011903A1 |
The invention relates to the use of a chitosan derivative comprising at least approximately 20 % of structural elements having general formula (I) wherein: R is a hydrogen atom, or a (C�1?-C�4?) alkylcarbonyl group wherein the alkyl ...
|
|
WO/1998/009981A1 |
Human salivary proteins CON-1 and CON-2 having alpha-glucosidase inhibitory activity and methods of using same for the treatment of diabetes and AIDS. The figure shows a comparison of carbohydratases activity in the presence of CON-1 as ...
|
|
WO/1998/009989A1 |
The use of a muramyl peptide compound in the preparation of an agent for the alleviation of immunosuppression is disclosed.
|
|
WO/1998/000153A1 |
The present invention is directed to amides of antibiotic A82846B (also known as chloroorienticin A), and of N?4�-derivatives of A82846B. The present amide compounds are useful as antibacterials, especially for the control of gram posi...
|
|
WO/1997/043308A1 |
The invention is directed to methods of inducing the release of at least one chemokine by administering an effective amount of a muramyl dipeptide compound ("MDP compound") to a mammal. Another aspect of the invention is directed to meth...
|
|
WO/1997/040067A1 |
Improved chemical process for preparing the compounds of formula (I), wherein: R1 represents (C9-C12)alkyl; M represents hydrogen, 'alpha'-D-mannopyranosyl or 6-O-acetyl-'alpha'-D-mannopyranosyl and Y represents an amino group of formula...
|
|
WO/1997/038702A1 |
The present invention is directed to certain glycopeptide dimers in which two glycopeptide units are covalently linked to one another through a modifiable amine on a saccharide. These dimers are useful as antibacterials, especially for t...
|
|
WO/1997/038706A1 |
The present invention is directed to certain glycopeptide dimers in which two glycopeptide units are covalently linked to one another through their disaccharide amine, via a linking radical. This invention is also directed to the monomer...
|
|
WO/1997/034623A1 |
The present invention relates to a library of distinct substances and compositions having the general formula R-P-S-L and P-S-L, representing solid support-bound lipoglycopeptides and free lipoglycopeptides, respectively. Combinatorial m...
|
|
WO/1997/032895A1 |
The invention provides a method of alleviating or preventing neuropathic pain in a subject by administering an effective amount of an active fragment of prosaposin to the subject. The invention also provides prosaposin-derived fragments ...
|
|
WO/1997/031941A2 |
The compounds of formula (I) cyclo[X11-Z12-X23-X34-Z25-X46]cyclo(2'beta'-5'beta') wherein: X1= (D or L)Cys(Y) or (D or L)SeCys(Y), Z1=Asp and Z2=Dap or Z1=Dap and Z2=Asp and X2, X3 and X4 = natural or synthetic hydrophobic amino acids, h...
|
|
WO/1997/026784A1 |
The present invention provides compositions and methods of inducing immune response in patients. In particular, it provides compositions useful in inducing humoral responses against desired immunogens, particularly polysaccharides.
|
|
WO/1997/025351A2 |
The present invention provides novel compounds comprising peptide sequences which mimic the conserved amino acid motif LDTSL of MAdCAM-1 and which have groups bonded to the N- and C-termini. Also provided are methods of inhibiting the in...
|
|
WO/1997/020855A2 |
A method of synthesis of a material corresponding to general formula R3 - X - H, characterised in that it comprises a material corresponding to general formula (I), being cleaved as indicated enzymatically or non-enzymatically using acid...
|
|
WO/1997/017470A1 |
The present invention relates to materials and methods for diagnosing breast cancer in humans. It is based, at least in part, on the discovery that a substantial percentage of human breast cancer tissue samples contained nucleic acid seq...
|
|
WO/1997/015585A1 |
Compounds represented by general formula (I) or their pharmaceutically acceptable salts which are useful as a selectin inhibitor and appropriately usable in the treatment or prevention of various inflammations, for example, inflammatory ...
|
|
WO/1997/015831A1 |
Compounds and libraries are labeled with a galactosyl epitope and then screened in accordance with an assay involving cells having a characteristic of interest. Conveniently, the screening may embody target cells, where the compounds are...
|
|
WO/1997/014966A1 |
A novel ligand regulatory pathway is disclosed and methods of activating the novel pathway in a cell expressing a ligand for an Eph subfamily receptor tyrosine kinase protein. Methods are provided for identifying substances capable of ac...
|
|
WO/1997/013783A1 |
The present invention relates to a novel synthetic acceptor peptide for the enzyme N-acetylgalactosaminyltransferase and its use for the control of glycosylation of a protein.
|
|
WO/1997/012894A1 |
The present invention provides a method for the preparation of disaccharides, such as glucosaminyl muramic acids peptides and derivatives. The method includes condensing a protected muramic acid ester with a 1-organothio- or 1-fluorogluc...
|
|
WO/1997/010259A1 |
The present invention pertains to medicine and veterinary science, more specifically, to a method of obtaining physiologically active muramyl peptides. The proposed method involves obtaining an activated ether of an unprotected N-acetyl ...
|
|
WO/1997/005889A1 |
Non-specific vaccination is achieved by administering muramyl or glucosaminylmuramyl peptides with D-amino acid residue in a second or third position from the proximal end. New methods for non-specific oral, vaginal, and topic vaccinatio...
|
|
WO/1997/003995A1 |
The present invention provides a method of synthesizing an allyl pentasaccharide having structure (I) as well as related oligosaccharide ceramides and other glycoconjugates useful as vaccines for inducing antibodies to epithelial cancer ...
|
|
WO/1997/002277A2 |
A transamination reaction of glycosyl-1-amine with a nucleophilic reagent containing an -NH2 or -NHNH2 group is used to prepare a broad spectrum of glycoconjugates by substitution of the 1-am ino group. The substitution reaction does not...
|
|
WO/1997/002288A1 |
Method for purifying antibiotic compounds of the dalbaheptide family by means of isoelectric focusing (IEF) in a multicompartment electrolyzer with immobiline membranes, in particular zwitterionic membranes. A further object of the inven...
|
|
WO/1996/040251A1 |
Compositions and methods are described for preventing and treating sepsis in humans and other animals. Surgical patients, low birth weight infants, burn and trauma victims, as well as other individuals at risk can be treated prophylactic...
|
|
WO/1996/040198A1 |
The present invention provides a process for synthesizing a glycopeptide having structure (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 are each independently H, OH, ORi, NH2, NHCORi, F, CH2OH, CH2ORi, or a substituted or unsubstituted ...
|
|
WO/1996/039160A1 |
A copolymer comprising an N-acylated derivative, and a composition comprising said copolymer and a polypeptide, said polypeptide comprising at least one effective ionogenic amine, wherein at least 50 percent, by weight, of said polypepti...
|
|
WO/1996/034005A1 |
The present invention provides a process for synthesizing a compound having structure (I), wherein R is H, as well as related oligosaccharides useful as a vaccine for inducing antibodies to human breast cancer cells in an adjuvant therap...
|
|
WO/1996/033162A1 |
Compounds of the formula: Ar-L-(*)m in which Ar represents a substantially planar, fused ring system which contains at least 4 aromatic rings and which is of formula (I) wherein: n is 0 or 1; 0 means that the surrounding ring is aromatic...
|
|
WO/1996/031532A1 |
The invention relates to cytostatics which are made tumour-specific by modification with sugar. Suitable spacers ensure serum-stability and intracellular effect at the same time.
|
|
WO/1996/031533A1 |
A pharmaceutical composition for stimulating the haematopoietic function and preventing the myelotoxic side-effects of some treatments, containing at least one water-soluble muramyl peptide derivative such as Muradimetide, muroctasine or...
|
|
WO/1996/030401A1 |
The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods ...
|
|
WO/1996/029339A1 |
Compounds of formula (I) wherein R is CH3 and R1 is a peptidic residue or R1 is OH and R is a peptidic residue have pharmacological activity as sialyl Lewis X mimetics, e.g. in the prevention or treatment of disorders or diseases which a...
|
|
WO/1996/028462A1 |
The invention concerns novel 17-difluoromethylene-oestratrienes of general formula (I), in which: R1 is a hydrogen atom or a C1-C10 alkyl group; R5 is a methyl or ethyl group; R2 is a hydrogen atom or an 'alpha'- or 'beta'-position C1-C1...
|
|
WO/1996/028467A1 |
This invention relates to novel compounds of general formula (I) and to pharmaceutical compositions containing them.
|
|
WO/1996/024615A1 |
The present invention discloses a new process for the purification of vancomycin hydrochloride by combining preparative chromatography on a silica gel column and the precipitation with ethanol from a salt-water-ethanolic solution without...
|
|
WO/1996/024614A1 |
The present invention discloses a new method for the purification of vancomycin hydrochloride by preparative HPLC (method of displacement chromatography), whereby the chromatographic purity of the product is essentially improved. The chr...
|
|
WO/1996/005863A1 |
The compound (W-Z-M) of the invention comprises an element (M) selected from the group consisting of markers and therapeutic agents having an intracellulary active site (S.A), linked to a ligand (W-Z) that comprises an arm (Z) linked to ...
|
|
WO/1995/032985A1 |
Disclosed are 3'-(4'-) modified nucleosides and nucleotides of general formula (1), wherein R' is hydrogen, mono-, di- or triphosphate, alkyl phosphonate, dialkyl phosphinate or phosphoramidite; X is oxygen, nitrogen, carbon or sulfur; Y...
|
|
WO/1995/031994A1 |
The invention relates to conjugates of poorly immunogenic antigens, e.g., peptides, proteins and polysaccharides, with a synthetic peptide carrier constituting a T cell epitope derived from the sequence of E. coli hsp65 (GroEL), or an an...
|
|
WO/1995/031480A1 |
Polypeptide compositions comprising two distinct subunits which can form 'alpha'-helical coiled-coil heterodimers are described. The two subunits can each have a different compound or bioactive moiety attached in a precisely-defined orie...
|
